Sanara MedTech (NASDAQ:SMTI) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Sanara MedTech (NASDAQ:SMTI) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $36.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday. Wall Street Zen cut Sanara MedTech from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, Zacks Research downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $41.00.

Sanara MedTech Stock Down 2.3%

NASDAQ:SMTI opened at $21.25 on Monday. Sanara MedTech has a 1 year low of $18.90 and a 1 year high of $37.91. The company has a current ratio of 1.80, a quick ratio of 1.60 and a debt-to-equity ratio of 7.34. The stock has a market cap of $189.13 million, a price-to-earnings ratio of -5.04 and a beta of 1.06. The stock has a 50-day moving average price of $22.84 and a two-hundred day moving average price of $27.28.

Sanara MedTech (NASDAQ:SMTI) last released its quarterly earnings data on Wednesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.33. Sanara MedTech had a negative return on equity of 21.33% and a negative net margin of 36.79%.The business had revenue of $26.33 million for the quarter, compared to analysts’ expectations of $26.63 million. As a group, equities analysts expect that Sanara MedTech will post -1.1 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Stonebridge Wealth Management LLC bought a new stake in shares of Sanara MedTech during the 2nd quarter worth approximately $3,397,000. Marshall Wace LLP increased its holdings in Sanara MedTech by 144.3% during the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after buying an additional 42,237 shares during the last quarter. Squarepoint Ops LLC raised its position in Sanara MedTech by 343.4% during the third quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock worth $996,000 after acquiring an additional 24,305 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in Sanara MedTech in the second quarter valued at $382,000. Finally, Vanguard Group Inc. lifted its stake in Sanara MedTech by 3.4% in the third quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after acquiring an additional 6,049 shares during the last quarter. Institutional investors and hedge funds own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.